Sequencing your real estate needs
Real estate requirements for life sciences companies are technically complex, capital intense, and atypical for real estate service providers whose primary focus is office or warehouse space. Time-to-market and funding are crucial factors in driving innovation and successful new pharmaceutical product launches, which, in turn, require laboratories, vivaria, pilot plants, and manufacturing facilities. Our specialists understand the pharmaceutical product life cycle as well as the technical complexities that can create significant budgetary and scheduling risks. We’ve successfully addressed the risks that surround real estate decision-making throughout all phases of the product life cycle and across all technical aspects of planning, designing, engineering, and constructing any type of life science space.Connect with my local life sciences real estate advisor
The centerpiece of our approach is how we integrate your technical and financial requirements into the deal negotiation process, ensuring these requirements are incorporated accurately into the transaction documents. This fully integrated process enables our team to develop innovative strategies with credible budgets and schedules at early transaction stages, providing clients with the facts needed to make more fully informed decisions.
This transparent, risk averse, “cradle-to-grave” model creates seamless continuity and allows complete flexibility, maximizing the efficacy of our client’s internal resources on either a portfolio or transactional basis.
- Strategic Real Estate Planning
- Site Selection
- Pre-Lease Budgeting and Scheduling
- Lease Negotiation
- Site Evaluation Due Diligence Oversight
- Consultant Team Selection, Engagement and Oversight
- Post-Lease Project Management
- Construction Management
Subscribe to Avison Young email communications for news, listing information, research reports and more.
Life sciences industry overview
Driven by an aging population, steady funding sources, and an urgent need to discover and develop vaccines and treatments for COVID-19, growth in life sciences industries shows no sign of slowing down. Unique location and space use requirements have made the sector resilient, drawing the attention of real estate investors.